| abstract |
1. A pharmaceutical formulation comprising 420-480 mg of eprosartan acid. 2.- A pharmaceutical formulation according to claim 1, comprising 440-463 mg, preferably 450 mg, of eprosartan acid. 3.- A pharmaceutical formulation. suitable for a mid-concentration dosage of the formulation according to claim 1, which comprises 210-240 mg of eprosartan acid.4.- A pharmaceutical formulation according to claim 3, which comprises 220-230 mg, preferably 225 mg, of eprosartan acid. 5. A pharmaceutical formulation according to any one of claims 1 to 4, in the form of an immediate release formulation. |